BRPI0817209A2 - Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas - Google Patents

Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas

Info

Publication number
BRPI0817209A2
BRPI0817209A2 BRPI0817209-9A2A BRPI0817209A BRPI0817209A2 BR PI0817209 A2 BRPI0817209 A2 BR PI0817209A2 BR PI0817209 A BRPI0817209 A BR PI0817209A BR PI0817209 A2 BRPI0817209 A2 BR PI0817209A2
Authority
BR
Brazil
Prior art keywords
intermaled
methods
long
polypeptide compositions
nuclear element
Prior art date
Application number
BRPI0817209-9A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Mario Ostrowski
R Bradley Jones
Ashish Agrawal
Frederick M Hecht
Original Assignee
David Gladstone Inst
Univ California
R Bradley Jones
Mario Ostrowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Gladstone Inst, Univ California, R Bradley Jones, Mario Ostrowski filed Critical David Gladstone Inst
Publication of BRPI0817209A2 publication Critical patent/BRPI0817209A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
BRPI0817209-9A2A 2007-09-20 2008-09-19 Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas BRPI0817209A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97399307P 2007-09-20 2007-09-20
PCT/US2008/010883 WO2009038756A2 (en) 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0817209A2 true BRPI0817209A2 (pt) 2015-03-10

Family

ID=40468692

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817209-9A2A BRPI0817209A2 (pt) 2007-09-20 2008-09-19 Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas

Country Status (11)

Country Link
US (1) US20110046042A1 (enExample)
EP (1) EP2200637A4 (enExample)
JP (1) JP2010539901A (enExample)
KR (1) KR20100075483A (enExample)
CN (1) CN101969987A (enExample)
AU (1) AU2008301888A1 (enExample)
BR (1) BRPI0817209A2 (enExample)
CA (1) CA2700115A1 (enExample)
MX (1) MX2010003110A (enExample)
RU (1) RU2010115088A (enExample)
WO (1) WO2009038756A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8647640B2 (en) 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
EP2625292B1 (en) * 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
US20150219662A1 (en) * 2012-06-28 2015-08-06 University Of Louisville Research Foundation, Inc. Use of protein line-1 orf-1 as a biomarker for cancer
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
JP6830660B2 (ja) * 2015-04-03 2021-02-17 国立大学法人京都大学 がんの治療薬のスクリーニング方法
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2021076977A1 (en) * 2019-10-16 2021-04-22 King Abdullah University Of Science And Technology Methods for modulating human l1 retrotransposons rna and compositions for use therein
US20230053473A1 (en) * 2019-12-26 2023-02-23 The Johns Hopkins University Enhancing expression of line-1 encoded orf2p for cancer therapeutics
EP4159745B1 (en) * 2020-06-02 2025-09-24 Tokyo Women's Medical University S100a8-inhibiting peptide and therapeutic drug for disease which containing same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280108A (en) * 1991-09-27 1994-01-18 United States Of America Antibodies to p40
ATE399022T1 (de) * 1995-10-20 2008-07-15 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
CN1315379A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸
CN1315332A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——l1－12和编码这种多肽的多核苷酸
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
CN1339478A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸
CN1339450A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸
CN1343776A (zh) * 2000-09-19 2002-04-10 上海博德基因开发有限公司 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸
CN1352094A (zh) * 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸
CN1425684A (zh) * 2001-12-19 2003-06-25 复旦大学 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸
AU2003294236A1 (en) * 2002-10-25 2004-05-25 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
EP1636343B1 (en) * 2003-05-28 2013-08-21 The Johns-Hopkins University Synthetic mammalian retrotransposon gene

Also Published As

Publication number Publication date
AU2008301888A1 (en) 2009-03-26
WO2009038756A2 (en) 2009-03-26
MX2010003110A (es) 2010-05-19
RU2010115088A (ru) 2011-10-27
WO2009038756A3 (en) 2009-05-14
KR20100075483A (ko) 2010-07-02
CN101969987A (zh) 2011-02-09
CA2700115A1 (en) 2009-03-26
EP2200637A4 (en) 2011-10-19
EP2200637A2 (en) 2010-06-30
JP2010539901A (ja) 2010-12-24
US20110046042A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
BRPI0817209A2 (pt) Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0810172A2 (pt) Polipeptídeos de fator vii modificado e seus usos
BRPI0813148A2 (pt) Composição condicionadora de tecido líquida e método de uso
DK3178835T3 (da) Forlængede rekombinante polypeptider og sammensætninger omfattende samme
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0906722A2 (pt) Métodos e composições usando polipeptídeos de fusão klotho-fgf
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
PT3812360T (pt) Compostos de monoclorotrifluoropropeno e composições e métodos utilizando os mesmos
BR112013010988A2 (pt) composição fluída e uso
BRPI0811871A2 (pt) Composições agroquímicas ácidas bioativas e uso das mesmas
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI1008280A2 (pt) Formulações prebióticas e métodos mde uso
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
BRPI0816389A2 (pt) Composições de celulase total fúngica filamentosa realçada por beta-glicosidade e métodos de uso
BRPI1007175A2 (pt) Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0821668A2 (pt) Uso
BRPI1007494A2 (pt) composto e uso do mesmo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]